MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT
Status:
Completed
Trial end date:
2019-04-09
Target enrollment:
Participant gender:
Summary
Tyrosine-kinase Inhibitors (TKI) resistance in gastrointestinal stromal tumours (GIST) is a
common problem after prolonged treatment periods. The main objectives of this monocentric
diagnostic Phase I/IIa study are safety and tolerability, pharmacokinetics and dosimetry of
68Ga-NeoBomb1 in GIST patients. The rationale behind this study is to improve diagnostic
accuracy in GIST via positron-emission tomography/computer tomography (PET-CT) with a focus
on TKI-resistant subtypes. Better detection, classification and definition of lesion extent
are expected from the use of 68Ga-NeoBOMB1.